Why Abridge matters
Abridge raised a $316 million Series E extension in April 2026 at the same $5.3 billion valuation set by its $300 million a16z-led Series E in June 2025, taking total funding to about $1.1 billion. More than 300 health systems use the platform, covering over 100 million clinical conversations a year. Duke Health rolled it out to 5,000 clinicians across 150-plus clinics in January 2025.
The numberAbout $1.1 billion raised at a $5.3B valuation after a $316M Series E extension in April 2026
North Carolina connection
Duke Health in Durham deployed Abridge to more than 5,000 clinicians across 150-plus clinics under an enterprise agreement announced January 9, 2025.
On The Agentic 80
Listed under Vertical agents. Agents built for one profession: law, finance, medicine, compliance.
On The All Things AI 100
Listed under Vertical AI and science. AI built for one field: law, medicine, drug discovery, finance.
Quick answers
- What does Abridge do?
- Ambient AI that turns clinician-patient conversations into clinical notes inside the EHR. Abridge raised a $316 million Series E extension in April 2026 at the same $5.3 billion valuation set by its $300 million a16z-led Series E in June 2025, taking total funding to about $1.1 billion.
- What AI capabilities does Abridge offer?
- Abridge provides ambient AI that listens to clinician-patient visits and drafts clinical notes for clinician review inside the electronic health record. The product also creates patient-facing visit summaries and supports documentation workflows used by health systems, including integration with Epic. Clinicians use it to capture encounter details during the visit rather than writing notes afterward.
- Why is Abridge on The Agentic 80?
- Abridge is listed under Vertical agents. Agents built for one profession: law, finance, medicine, compliance. About $1.1 billion raised at a $5.3B valuation after a $316M Series E extension in April 2026.
- Why is Abridge on The All Things AI 100?
- Abridge is listed under Vertical AI and science. AI built for one field: law, medicine, drug discovery, finance. About $1.1 billion raised at a $5.3B valuation after a $316M Series E extension in April 2026.
- Where is Abridge based, and who owns it?
- Abridge is based in Pittsburgh, PA, was founded in 2018 and is private, Series E.